Taysha Gene Therapies' positive results from the REVEAL study showcase TSHA-102's promise in treating Rett Syndrome. Click ...

PolyActiva is taking its high-precision glaucoma implant to global trials in a test for Australia’s biotech ambitions.

Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales ...

ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

The global Electronic Lab Notebook Market, valued at US$0.68 billion in 2024 stood at US$0.72 billion in 2025 and is projected to advance at ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

The installation was finalized during Q1 2025 and supports critical pharmaceutical storage and cold chain logistics operations. This deployment represents the continuation of a multi-year relationship ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

Instead of approving Stealth BioTherapeutics' drug for Barth syndrome, the FDA withheld its endorsement, but decided it may ...